CJC-1295 / Ipamorelin 5mg/5mg

CJC-1295 / Ipamorelin is engineered as a synergistic dual-secretagogue peptide matrix, combining a Growth Hormone Releasing Hormone (GHRH) analog with a selective Growth Hormone Secretagogue Receptor (GHSR) agonist to facilitate specialized somatotropic axis research.

• GHRH Receptor Activation (CJC-1295): Stimulates the anterior pituitary gland to enhance baseline Growth Hormone (GH) synthesis and continuous signal amplification without desensitizing receptor responsiveness.

• Selective Ghrelin-Mimetic Signaling (Ipamorelin): Selectively targets the GHSR-1a receptor to trigger potent, pulsatile GH release while exhibiting zero affinity for cortisol, prolactin, or appetite-stimulating pathways.

While single-agent secretagogue models provide isolated GH spikes, the CJC-1295 / Ipamorelin combination co-activates both GHRH and ghrelin receptor pathways—allowing researchers to investigate sustained GH pulsatility, accelerated cellular recovery, and nitrogen retention without off-target hormonal elevations.

Disclaimer: This product is sold strictly for research purposes only. Not for human consumption, clinical trials, or therapeutic use.